iTeos Therapeutics, Inc.
ITOSNASDAQHealthcare
$10.15
+$0.02(+0.20%)
Market Cap$448684810
P/E Ratio—
52W High$17.63
52W Low$4.8
iTeos Therapeutics, Inc. (ITOS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ITOS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $35.00M | $12.60M | $267.63M | $344.77M | $0.00M |
| Cost of Revenue | $1.24M | $0.90M | $0.81M | $0.61M | $0.54M |
| Gross Profit | $33.76M | $11.70M | $266.82M | $344.16M | ($0.54M) |
| Gross Margin %(computed) | 96.46% | 92.87% | 99.70% | 99.82% | — |
| Operating Expenses | |||||
| R&D Expenses | $145.45M | $113.30M | $97.36M | $59.37M | $29.90M |
| G&A Expenses | $49.08M | $50.40M | $43.95M | $40.51M | $15.34M |
| Total Operating Expenses | $193.29M | $162.80M | $140.49M | $99.26M | $44.70M |
| Operating Income | ($159.53M) | ($151.10M) | $126.32M | $244.90M | ($45.24M) |
| Operating Margin %(computed) | -455.79% | — | 47.20% | 71.03% | — |
| Interest Income | $30.87M | $31.77M | $11.36M | $0.08M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($120.34M) | ($109.03M) | $148.74M | $256.46M | ($38.09M) |
| Income Tax Expense | $14.07M | $3.61M | $52.08M | $41.94M | ($0.06M) |
| Net Income | ($134.41M) | ($112.64M) | $96.65M | $214.52M | ($38.03M) |
| Net Margin %(computed) | -384.04% | -894.34% | 36.11% | 62.22% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.32 | $-3.15 | $2.72 | $6.10 | $-1.24 |
| Wtd Avg Shares | 40.47M | 35.76M | 35.55M | 35.18M | 35.04M |
| EBITDA | ($121.82M) | ($111.66M) | $148.38M | $257.08M | ($37.84M) |
| EBITDA Margin %(computed) | -348.07% | -886.53% | 55.44% | 74.56% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more iTeos Therapeutics, Inc. data
About iTeos Therapeutics, Inc. (ITOS) Income Statement
iTeos Therapeutics, Inc. (ITOS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ITOS reported revenue of $0.04B, gross profit of $0.03B (gross margin 96.46%), and net income of ($0.13B) — a net profit margin of -384.04%.
Frequently asked questions
ITOS · 4 questionsiTeos Therapeutics, Inc. (ITOS) reported revenue of $0.04B for 2024, up 177.9% year-over-year.
ITOS revenueITOS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09